StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PR9-R.BK$16.50+0.00%
Fair $16.50+0.0%

PR9-R.BK

Praram 9 Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$16.50

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $16.50Fund rank 37/100 · Data gapFallback financials|
SA 43/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $497.0M · quality 78.7/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 80/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · PR9-R.BKLocal privado en este navegador · Praram 9 Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$13.0B

P/E

35.3x

↑

EV/EBITDA

9.3x

↓

ROE

14.0%

↑

Gross Margin

36.6%

↓

Debt/Equity

0.00

↓
52-Week Range$17
$16$17

TradingView lightweight chart

PR9-R.BK price, volumen y niveles de valoración

Último $16.50Periodo +0.0%
Fair value: $16.50

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.7%

FCF CAGR

-14.4%

FCF margin

8.7%

FCF / Net income

0.56x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $5.28B · net income $822.7M · FCF $458.3M

2022-FY → 2025-FY

Gross margin

36.6%+2.9% pts

Operating margin

17.9%+1.5% pts

Net margin

15.6%+1.8% pts

FCF margin

8.7%-9.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$5.28B$5.28B$4.64B$4.20B$4.11B
Net Income$822.7M$822.7M$712.7M$557.9M$567.6M
EBITDA$1.33B$1.33B$1.17B$988.2M$1.00B
EPS——0.910.710.72
Gross Margin36.6%36.6%34.3%32.9%33.7%
Operating Margin17.9%17.9%17.1%15.4%16.5%
Net Margin15.6%15.6%15.4%13.3%13.8%
Balance Sheet
Debt/Equity0.000.000.000.000.00
Current Ratio3.773.77———
Cash Flow
Free Cash Flow$458.3M$458.3M$790.6M$497.0M$729.5M
Returns
ROE14.0%14.0%13.1%11.0%12.0%
Valuation
P/E35.2635.26———
EV/EBITDA9.299.29———
P/B2.212.21———
Growth & Yield
Revenue Growth13.8%13.8%10.3%2.3%—
EPS Growth——28.2%-1.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

n/dx → n/dx

EPS bridge

0.91 → n/d

Residual

+0.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.